Related references
Note: Only part of the references are listed.Inflammatory cell death induced by cytotoxic lymphocytes: a dangerous but necessary liaison
Diego de Miguel et al.
FEBS JOURNAL (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers
Riccardo Lobefaro et al.
LUNG CANCER (2021)
Associations between peripheral blood lymphocyte subsets and clinical outcomes in patients with lung cancer treated with immune checkpoint inhibitor
Peng Li et al.
ANNALS OF PALLIATIVE MEDICINE (2021)
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC
Jhanelle E. Gray et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy
Hiroshi Kagamu et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer
Selene Ottonello et al.
FRONTIERS IN IMMUNOLOGY (2020)
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data
Filippo G. Dall'Olio et al.
LUNG CANCER (2020)
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
Barzin Y. Nabet et al.
CELL (2020)
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?
Giuseppe Badalamenti et al.
CELLULAR IMMUNOLOGY (2019)
Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis
Ila Datar et al.
CLINICAL CANCER RESEARCH (2019)
Cytotoxic Function and Cytokine Production of Natural Killer Cells and Natural Killer T-Like Cells in Systemic Lupus Erythematosis Regulation with Interleukin-15
Syh-Jae Lin et al.
MEDIATORS OF INFLAMMATION (2019)
The Tumor Microenvironment Innately Modulates Cancer Progression
Dominique C. Hinshaw et al.
CANCER RESEARCH (2019)
Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer
Dickran Kazandjian et al.
JAMA ONCOLOGY (2019)
Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade
Florian Huemer et al.
JOURNAL OF CLINICAL MEDICINE (2019)
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
M. Majem et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
The circulating pool of functionally competent NK and CD8+cells predicts the outcome of anti-PD1 treatment in advanced NSCLC
Giulia Mazzaschi et al.
LUNG CANCER (2019)
Circulating NKp46+ Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung Cancer
Emilie Picard et al.
ONCOIMMUNOLOGY (2019)
Circulating CD56bright NK cells inversely correlate with survival of melanoma patients
Kaat de Jonge et al.
SCIENTIFIC REPORTS (2019)
Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab
Junko Tanizaki et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
Daniela S. Thommen et al.
NATURE MEDICINE (2018)
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Carsten Krieg et al.
NATURE MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Intratumoral CD56bright natural killer cells are associated with improved survival in bladder cancer
Neelam Mukherjee et al.
Oncotarget (2018)
CD56bright NK cells exhibit potent antitumor responses following IL-15 priming
Julia A. Wagner et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Phenotypic and Functional Properties of Tumor-Infiltrating Regulatory T Cells
Gap Ryol Lee
MEDIATORS OF INFLAMMATION (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The Untold Story of Granzymes in Oncoimmunology: Novel Opportunities with Old Acquaintances
Maykel Arias et al.
TRENDS IN CANCER (2017)
Evaluation of peripheral blood T lymphocyte surface activation markers and transcription factors in patients with early stage non-small cell lung cancer
Jacek Rutkowski et al.
CELLULAR IMMUNOLOGY (2017)
Checkpoint Blockade in Lung Cancer and Mesothelioma
Lysanne A. Lievense et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. E. Postmus et al.
ANNALS OF ONCOLOGY (2017)
Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients
Danay Saavedra et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Prognostic role of lactate dehydrogenase in solid tumors: A systematic review and meta-analysis of 76 studies
Fausto Petrelli et al.
ACTA ONCOLOGICA (2015)
Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
Albert Lo et al.
CANCER RESEARCH (2015)
How Do Cytotoxic Lymphocytes Kill Cancer Cells?
Luis Martinez-Lostao et al.
CLINICAL CANCER RESEARCH (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer
Ramon Rami-Porta et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition
Eric O. Long et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Functional significance of CD57 expression on human NK cells and relevance to disease
Carolyn M. Nielsen et al.
FRONTIERS IN IMMUNOLOGY (2013)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer
Shinichiro Motohashi et al.
CLINICAL IMMUNOLOGY (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56BrightCD16- cells and display an impaired capability to kill tumor cells
Paolo Carrega et al.
CANCER (2008)
Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance
Xuefang Cao et al.
IMMUNITY (2007)
Share Paper
